Actualités sur Medikament
- plus
MSD Expands Operations in Switzerland
Lucerne (ots) - - Company will open a new location in Zurich, focused on accelerating research, data and commercialization of our medicines and vaccines - Lucerne will remain the center of MSD's presence in Switzerland MSD (Merck Sharp & Dohme AG) today announced that it will establish a new office in Zurich, Switzerland, aimed at accelerating the ...
Un documentplusZentiva Celebrates The Parc's Impressive Scientific Track Record in 2019
Prague (ots/PRNewswire) - Zentiva welcomed The Pharmaceutical Applied Research Center (The Parc) to their Prague headquarters to celebrate the first anniversary of The Parc Awards. The Parc is a unique research platform designed to prepare future generations of pharmaceutical scientists and engineers. Twenty-nine students are currently included in the program and an ...
plusSwissmedic grants approval for pembrolizumab (KEYTRUDA®) in combination with axitinib (Inlyta®) for first-line therapy of advanced renal cell carcinoma(1)
Lucerne (ots) - - Swissmedic approval is based on a significant benefit in overall survival with pembrolizumab in combination with axitinib compared to sunitinib in the Phase III study KEYNOTE-426 - Pembrolizumab is the first PD-1 inhibitor that has ...
Un documentplusCOMPASS Pathways Granted Patent Covering Use of Its Psilocybin Formulation in Addressing Treatment-resistant Depression
London (ots/PRNewswire) - COMPASS Pathways, a mental health care company, announced today that it has been granted US Patent No 10,519,175, relating to methods of treating drug-resistant depression with a psilocybin formulation, by the US Patent and Trademark Office. The patent covers the use of COMPASS's ...
plusNovadiscovery raises series A financing to scale its in silico clinical trial platform - Debiopharm leads the round with EUR 5 million
Lausanne (ots) - - Novadiscovery pioneers the use of in silico clinical trials to predict drug efficacy and optimize clinical development, an approach meeting the strong expectations from pharmaceutical companies for faster and more efficient development, and benefiting from increased endorsement from health ...
plusSenzer's Pharmaceutical Inhaler Selected for Major Cannabinoid Patient Registry
London (ots/PRNewswire) - Senzer's pharmaceutical respiratory device will be used in Europe's first and biggest national medical cannabis registry, Project TWENTY21, in which an expected 20,000 patients will be enrolled by the end of 2021 creating the largest body of evidence for the efficacy of medical cannabis. Drug Science, the leading independent scientific body on ...
plusKyowa Kirin Announces Marketing Authorisation Application for Istradefylline Validated by European Medicines Agency
Tokyo (ots/PRNewswire) - Kyowa Kirin Co., Ltd. (TSE: 4151) President and CEO: Masashi Miyamoto, "Kyowa Kirin") today announces that its marketing authorisation application (MAA) for istradefylline (KW-6002) as an adjunctive treatment to levodopa-based regimens in adult patients with Parkinson's disease (PD) ...
plusLarge Real-World Data Confirm Safety and Effectiveness of LIXIANA® (edoxaban) in Routine Clinical Practice for Elderly AF Patients with Comorbidities
Munich (ots/PRNewswire) - · Results published in the European Heart Journal - Cardiovascular Pharmacotherapy (https://academic.oup.com/ehjcvp/advance-article-abstract/doi/10.1093/ehjcvp/pvz070/5644339?redirectedFrom=fulltext), showed rates of thromboembolism similar to those observed in the ENGAGE AF-TIMI 48 ...
plusCOMPASS Pathways and King's College London Announce Results From Psilocybin Study In Healthy Volunteers
London (ots/PRNewswire) - COMP360 (psilocybin) was well tolerated in healthy volunteers and results support further investigation of simultaneous 1:1 therapeutic administration design COMPASS Pathways, a mental health care company, has reported that its COMP360 (psilocybin) was well-tolerated when administered to ...
plusSchweizerischer Nationalfonds / Fonds national suisse
Big Data makes intensive care better
Bern (ots) - Patient safety in intensive care units could be significantly improved if false alarms could be greatly reduced and critical complications such as epileptic seizures could be predicted. This is where the "ICU Cockpit" project of the National Research Programme "Big Data" (NRP 75) comes in: The large amounts of data from intensive care medicine will be used to develop procedures for early warning systems and ...
plusSenzer's Respiratory Cannabinoid Device Notches Up Another Design Award
London (ots/PRNewswire) - Senzer's pharmaceutical cannabinoid device has won another major design award, with the German Design Council commending the unique inhaler for having 'a clear modern design that perfectly combines ergonomics and functionality'. The award is the third design success for Senzer's Class IIa Medical Device, which is breath-activated and delivers ...
plusHitachi Medical Systems Europe Holding AG
2Hitachi and Centre Léon Bérard cancer center in Lyon to launch a research collaboration in the fight against cancer with AI
plusLOG Pharma Packaging to Launch ActiveGuard® CONNECT(TM) at CPhI Worldwide 2019
Frankfurt, Germany (ots/PRNewswire) - Smart packaging solution boosts medication adherence by 23% LOG Pharma Packaging announced today that it will launch its innovative patent pending line of ActiveGuard® CONNECT(TM) smart packaging solutions at CPhI Worldwide 2019 in Frankfurt, Germany from 5-7 November. ActiveGuard® CONNECT(TM) was developed in cooperation with ...
plusRESTORE 1st Advanced Therapies Science Meeting
Berlin (ots/PRNewswire) - 25th-26th November 2019, Berlin RESTORE-Health by Advanced Therapies invites you to join the First Advanced Therapies Science Meeting (ATSM), an EACCME® accredited event, which will be held at the Maritim Hotel, Stauffenbergstraße in Berlin from the 25th - 26th November 2019. Advanced Therapies are one of the most recent and significant advances in medicine. They include gene and cell therapies ...
plusEuropean Commission Approves BAVENCIO® (avelumab) Plus Axitinib Combination for First-Line Treatment of Patients With Advanced Renal Cell Carcinoma
Not intended for US, Canada and UK-based media -- EU approval based on JAVELIN Renal 101 trial results demonstrating significant improvement in progression-free survival with BAVENCIO in combination with axitinib compared with sunitinib -- Combination regimen approved across all IMDC prognostic risk groups and ...
plusZentiva Acquires Central and Eastern European Business of Alvogen
Zentiva to further expand its geographical footprint and complement its portfolio in Generics and OTC Prague, Czech Republic and Sofia, Bulgaria (ots/PRNewswire) - Zentiva announces the signing of a definitive agreement to acquire the Central and Eastern European Business of Alvogen, for an undisclosed amount. Alvogen CEE markets over 200 generic and over-the-counter ...
plusUEG Week Exhibition Celebrates 50 Years of Colonoscopy in Preventing and Diagnosing Gastrointestinal Diseases, Including Colorectal Cancer
Barcelona, Spain (ots/PRNewswire) - An interactive exhibition celebrating the 50th anniversary since the completion of the first successful colonoscopy has been launched at the United European Gastroenterology (UEG) Week in Barcelona. The educational exhibition is jointly supported by Norgine, Fujifilm and Olympus ...
plus- Oral ferric maltol may offer an alternative treatment option to IV iron even in patients who have failed or not tolerated current oral iron treatments[1]
Amsterdam (ots/PRNewswire) - Norgine B.V. highlighted new data from a study supported by its partner company Shield Therapeutics, presented today at the United European Gastroenterology (UEG) Week in Barcelona showing that ferric maltol, a novel oral iron replacement therapy, was found to be non-inferior to ...
plusEuropean Results From Global ETNA-AF Registry Show Low Bleeding and Low Cardiovascular Event Rates in Elderly NVAF Patients on LIXIANA® (edoxaban)
- One-year outcomes of real-world edoxaban-treated European patients from the Global ETNA-AF registry showed low rates of potentially life-threatening bleeding and low CV events in elderly NVAF patients1 - The Global ETNA-AF programme is currently the largest and most comprehensive repository of routine clinical ...
plusFirst Digital Health Osteoarthritis Wearable Glove System Starts Pre-launch Pilot Trial Series & Medical Tests
Madrid (ots/PRNewswire) - QUANTIC NANOTECH (https://qnanotech.com/), a product division of Spanish DEMAC S.A. group who presented the first home wearable osteoarthritis treatment glove system "QNANO GLOVE (https://qnanotech.com/)" during the last CES 2019 Edition in Las Vegas, announced today the opening of free ...
plusHovione Announces Successful End-of-phase 2 Meeting With the FDA and Outlines Phase 3 Program for Minocycline Topical Gel
Cork, Ireland (ots/PRNewswire) - Hovione announced details of its planned MARS-2 and MARS-3 (Minocycline Against Rosacea Study) Phase 3 development program for the treatment of moderate to severe inflammatory rosacea. At a recent End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA), Hovione ...
plusCHMP Adopts Positive Opinion for BAVENCIO® (avelumab) Plus Axitinib for First-Line Treatment of Patients with Advanced Renal Cell Carcinoma
Not intended for US, Canada and UK-based media - Opinion based on Phase III data showing combination lowered risk of disease progression or death by 31% and improved objective response rate compared with sunitinib1 - Decision by the European Commission anticipated in fourth quarter of 2019 Darmstadt, Germany and ...
plusSenzer's Medical Device Approved in Europe for the Safe and Effective Delivery of Cannabinoids
London (ots/PRNewswire) - Senzer Pharmaceuticals has been granted a CE Mark that certifies its inhaler as a medical device, allowing it to now be available for patients in Europe for the 'safe and effective delivery of pharmaceutical cannabinoids.' The Class IIa Medical Device approval is the first-ever in the cannabinoid space and clears the way for the UK-based ...
plusOral semaglutide improves glycaemic control in people with type 2 diabetes across baseline blood sugar levels
Barcelona, Spain (ots/PRNewswire) - Novo Nordisk today announced findings from an exploratory analysis of the PIONEER trial programme, showing oral semaglutide (3, 7 and 14 mg) improved glycaemic control in people with type 2 diabetes across baseline HbA1c levels. Greater reductions in HbA1c were demonstrated with 7 ...
plusFiasp® Demonstrated Effective Overall Blood Sugar Reductions in People With Advanced Type 2 Diabetes Uncontrolled on Multiple Daily Injections (Basal-bolus Regimen)
Bagsværd, Denmark (ots/PRNewswire) - New data presented today at the 55th Annual Meeting of the European Association for the Study of Diabetes (EASD) showed that, for people with advanced type 2 diabetes (>=10 years of diagnosis) not optimally controlled on their current basal-bolus regimen, Fiasp® (fast-acting ...
plusSofWave Medical's Low-Divergence Ultrasound Technology Has Received FDA Clearance for the Aesthetic Treatment of Facial Lines and Wrinkles
Yoqneam, Israel (ots/PRNewswire) - Sofwave Medical Ltd., an emerging aesthetic device company, announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Sofwave system. The Sofwave device is indicated for use as a non-invasive aesthetic treatment to improve facial lines ...
plusHelsana report shows: Medical services on the rise
Zürich (ots) - The "Volume Report" published today by Helsana elucidates the development of medical treatments. In Switzerland, increasing numbers of patients make use of medical treatments. As a result there is an increased need for coordination. General practitioners have less and less time to perform this role. The report finds great potential to meet these coordination needs in other health occupations. In its latest ...
plusMerck Announces FDA Breakthrough Therapy Designation for Investigational Therapy Tepotinib in Patients with Metastatic NSCLC with METex14 Skipping Alterations
- Investigational oral MET inhibitor has previously received SAKIGAKE 'fast-track' regulatory designation in Japan - MET exon 14 skipping alterations and MET amplifications are present in 3-5% of non-small cell lung cancer patients and correlate with poor prognosis - The designation is based on data from the ...
plusZentiva Enhances its Global Manufacturing Footprint by Signing an Agreement to Acquire Manufacturing Site in Ankleshwar, India
Prague, Mumbai and Ankleshwar, India (ots/PRNewswire) - Zentiva Group, a.s. announces the signing of a Business Transfer Agreement with Sanofi to acquire their manufacturing site in Ankleshwar, India. This acquisition will help ensure the continued supply of high-quality medicines to more patients by expanding the ...
plus